10623 results about "Diluent" patented technology

Method for carrying out the recovery of an intact volume of tissue wherein a delivery cannula tip is positioned in confronting adjacency with the volume of tissue to be recovered. The electrosurgical generator employed to form an arc at a capture component extending from the tip is configured having a resistance-power profile which permits recovery of the specimen without excessive thermal artifact while providing sufficient power to sustain a cutting arc. For the recovery procedure, a local anesthetic employing a diluent which exhibits a higher resistivity is utilized and the method for deploying the capture component involves an intermittent formation of a cutting arc with capture component actuation interspersed with pauses of duration effective to evacuate any accumulation or pockets of local anesthetic solution encountered by the cutting electrodes.

Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal. The methods involve applying to the skin of the animal a pharmaceutical composition that contains a therapeutically effective amount of one or more than one avenanthramide, an optional ecto and/or endo-parasiticidal agent, and a pharmaceutically acceptable diluent or carrier

Compounds of the formulas LAn-Z-X-WwD and BZ-X-WwD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and/or excipient, and methods of delivery the drug D via the compounds.

The use of extracts from the plant Hypericum perforatum in the preparation of pharmaceutical compositions for the treatment of hepatitis C, chronic hepatitis C and related viruses, said pharmaceutical compositions comprising at least one extract of the plant Hypericum perforatum and optionally in addition, one or more pharmaceutically acceptable inactive components, selected from, carriers, coatings, diluents and adjuvants.

A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and/or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and/or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.

The present application describes a product mixing device. The product mixing device includes an ingredient combination chamber and means for agitation positioned about the ingredient combination chamber. The ingredient combination chamber includes a diluent inlet, a number of macro-ingredient inlets, a number of micro-ingredient inlets, and an outlet.

Disclosed is a method for sharply reducing diurnal breathing loss emissions from automotive evaporative emissions control systems by providing multiple layers, or stages, of adsorbents. On the fuel source-side of an emissions control system canister, high working capacity carbons are preferred in a first canister (adsorb) region. In subsequent canister region(s) on the vent-side, the preferred adsorbent should exhibit a flat or flattened adsorption isotherm on a volumetric basis and relatively lower capacity for high concentration vapors as compared with the fuel source-side adsorbent. Multiple approaches are described for attaining the preferred properties for the vent-side canister region. One approach is to use a filler and/or voidages as a volumetric diluent for flattening an adsorption isotherm. Another approach is to employ an adsorbent with the desired adsorption isotherm properties and to process it into an appropriate shape or form without necessarily requiring any special provision for dilution. The improved combination of high working capacity carbons on the fuel source-side and preferred lower working capacity adsorbent on the vent-side provides substantially lower diurnal breathing emissions without a significant loss in working capacity or increase in flow restriction compared with known adsorbents used in canister configurations for automotive emissions control systems.

A low or no pollution power generation system is provided. The system has an air separator to collect oxygen. A gas generator is provided with inputs for the oxygen and a hydrocarbon fuel. The fuel and oxygen are combusted within the gas generator, forming water and carbon dioxide. Water or other diluents are also delivered into the gas generator to control temperature of the combustion products. The combustion products are then expanded through at least one turbine or other expander to deliver output power. The combustion products are then passed through a separator where the steam is condensed. A portion of the water is discharged and the remainder is routed back to the gas generator as diluent. The carbon dioxide can be conditioned for sequestration. The system can be optimized by adding multiple expanders, reheaters and water diluent preheaters, and by preheating air for an ion transfer membrane oxygen separation.

A system for managing bulk liquids for an automated clinical analyzer. The system comprises (a) at least one local reservoir for storing a bulk liquid for impending use, (b) at least one container for holding a bulk liquid before the liquid is transferred to a local reservoir, and (c) a controller for monitoring the level of a bulk liquid in a local reservoir. The local reservoir for storing a bulk liquid for impending use can be a trough. The use of troughs for storing a reagent, a diluent, or some other treating agent for impending use enables an aspirating/dispensing device having a plurality of pipettes to aspirate and dispense the reagent, diluent, or other treating agent at a high rate of throughput. The controller can monitor the level of a liquid in (a) a local reservoir for storing a bulk liquid for imminent use and the level of liquid in a (b) container for holding a bulk liquid before the liquid is transferred to a local reservoir. In the laboratory automation system described herein, the container for holding a bulk liquid before the liquid is transferred to a local reservoir can be a bottle. Other desirable features in the system include, but are not limited to, pump(s), valves, liquid level sensors.

This invention relates to a process to produce a polyalpha-olefin comprising: 1) contacting one or more alpha-olefin monomers having 3 to 24 carbon atoms with an unbridged substituted bis cyclopentadienyl transition metal compound having: 1) at least one non-isoolefin substitution on both cyclopentadientyl rings, or 2) at least two substitutions on at least one cyclopentadienyl ring, a non-coordinating anion activator, and optionally an alkyl-aluminum compound, where the molar ratio of transition metal compound to activator is 10:1 to 0.1:1, and if the alkyl aluminum compound is present then the molar ratio of alkyl aluminum compound to transition metal compound is 1:4 to 4000:1, under polymerization conditions wherein: i) hydrogen is present at a partial pressure of 0.1 to 50 psi, based upon the total pressure of the reactor or the concentration of the hydrogen is from 1 to 10,000 ppm or less by weight; ii) wherein the alpha-olefin monomer(s) having 3 to 24 carbon atoms are present at 10 volume % or more based upon the total volume of the catalyst/activator/alkylaluminum compound solutions, monomers, and any diluents or solvents present in the reaction; iii) the residence time of the reaction is at least 5 minutes; iv) the productivity of the process is at least 43,000 grams of total product per gram of transition metal compound; v) the process is continuous or semi-continuous, and vi) the temperature in the reaction zone does not rise by more than 10° C. during the reaction; and vii) ethylene is not present at more than 30 volume % of the monomers entering the reaction zone; and 2) obtaining a polyalpha-olefin (PAO), optionally hydrogenating the PAO, wherein the PAO comprises at least 50 mole % of a C3 to C24 alpha-olefin monomer, and wherein the PAO has a kinematic viscosity at 100° C. of 20 cSt or less.

A process for the production of ultrafine powders that includes subjecting a mixture of precursor metal compound and a non-reactant diluent phase to mechanical milling whereby the process of mechanical activation reduces the microstructure of the mixture to the form of nano-sized grains of the metal compound uniformly dispersed in the diluent phase. The process also includes heat treating the mixture of nano-sized grains of the metal compound uniformly dispersed in the diluent phase to convert the nano-sized grains of the metal compound into a metal oxide phase. The process further includes removing the diluent phase such that the nano-sized grains of the metal oxide phase are left behind in the form of an ultrafine powder.

The present invention is directed to a system, method, and computer program product for handling, mixing, dispensing and/or injecting a mixture into an individual during a medical procedure. The present invention provides one or more mixing devices, containers, and dispensing devices to facilitate the handling, mixing, dispensing, and/or injecting of a mixture containing, for example, pharmaceutical agents and/or radiopharmaceutical agents. The present invention also provides a mixing device capable of diluting a radiopharmaceutical agent with, for instance, a diluent, for altering a radiation dose emitted by the radiopharmaceutical agent.

A process for producing polyolefins having a bimodal molecular weight distribution, the process comprising producing a first polyolefin fraction in the presence of a catalyst in a first loop reactor, and producing a second polyolefin fraction in the presence of the catalyst in a second loop reactor which is serially connected to and downstream of the first loop reactor, the first and second polyolefin fractions being blended in the second loop reactor to form a polyolefin having a bimodal molecular weight distribution, at least the first loop reactor containing a diluent under supercritical conditions which is circulated around the loop of the reactor, and wherein at least the first loop reactor is provided with a fluff concentrating device communicating with the loop and in which polyolefin fluff of the first fraction is concentrated in the supercritical diluent, and polyolefin fluff of the first polyolefin fraction is transferred together with an amount of supercritical diluent from the fluff concentrating device of the first loop reactor into the second loop reactor.

The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.